{"nctId":"NCT01947491","briefTitle":"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis","startDateStruct":{"date":"2013-11"},"conditions":["Psoriasis"],"count":394,"armGroups":[{"label":"DFD01 Spray","type":"EXPERIMENTAL","interventionNames":["Drug: DFD01 Spray"]},{"label":"Vehicle Spray","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Spray"]},{"label":"Comp01 Lotion","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comp01 Lotion"]},{"label":"Vehicle Lotion","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Lotion"]}],"interventions":[{"name":"DFD01 Spray","otherNames":["Topical corticosteroid spray"]},{"name":"Comp01 Lotion","otherNames":["Topical corticosteroid lotion"]},{"name":"Vehicle Lotion","otherNames":[]},{"name":"Vehicle Spray","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque-type psoriasis.\n* Subjects with psoriasis involving 10 to 20% BSA, not including the face, scalp, groin, axillae and other intertriginous areas.\n* Subjects must have an IGA grade of 3 (moderate) at the Baseline Visit\n\nExclusion Criteria:\n\n* Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.\n* Other inflammatory skin disease that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis).\n* Presence of pigmentation, extensive scarring, or pigmented lesions or sunburn which could interfere with the rating of efficacy parameters.\n* History of psoriasis unresponsive to topical treatments.\n* History of organ transplant requiring immunosuppression, HIV, or other immunocompromised state.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Success According to the Investigator Global Assessment (IGA)","description":"IGA of clear or almost clear","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":173},"commonTop":["Application Site Pain","Application Site Pruritis"]}}}